Ocugen Inc. stock falls 2.35 percent amid broader market downturn

11 articles · Updated · MarketWatch · Apr 28

Shares closed at $1.66 on Tuesday, 39.08% below the 52-week high of $2.73 reached on March 17.
Trading volume was 4.5 million, significantly lower than the 50-day average of 8.8 million, highlighting reduced investor activity.
The decline outpaced the S&P 500's 0.49% and Dow Jones' 0.05% drops, reflecting Ocugen's underperformance during a generally weak session.

Amid a biotech M&A frenzy, is Ocugen a prime acquisition target for big pharma?

With a 'going concern' warning, can Ocugen's cash last until its first potential drug approval in 2027?

What are the biggest regulatory hurdles facing Ocugen's novel gene-agnostic therapies before they can reach patients?

Will Ocugen's lead drug become the first approved gene therapy for a broad range of retinitis pigmentosa patients?

Is a 31% efficacy rate for OCU410 truly competitive enough to disrupt the geographic atrophy market?